Incidence and predictors of vascular complications after invasive coronary procedures: A prospective analysis

Vascular Disease Management

Volumn 5, Issue 1, 2008, Pages 6-9

  Penugonda, Neelima ^a,b   Jones, Jennifer ^a   Spears, J Richard ^a   Schreiber, Theodore ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE;

ADULT; AGED; ANGIOGRAPHY; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD TRANSFUSION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FALSE ANEURYSM; FEMALE; HEART CATHETER; HEMATOMA; HOSPITALIZATION; HUMAN; INCIDENCE; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RETROPERITONEAL HEMORRHAGE; TERTIARY HEALTH CARE; URBAN AREA; VASCULAR DISEASE;

EID: 39449131086     PISSN: 15538036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sherev DA, Shaw RE, Brent BN. Angiographic predictors of femoral access site complications: Implication for planned percutaneous coronary intervention. Catheter Cardiovasc Interv 2005;65:196-202.
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696.
3. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000;356:2037-2044.
4. Chandrasekhar B, Doucet S, Bilodeau L, et al. Complications of cardiac catheterization in the current era: A single-center experience. Catheter Cardiovasc Interv 2001;52:289-295.
5. Blankenship JC, Tasissa G, O'Shea JC, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001;38:653-658.
6. Cohen DJ, O'Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced suppression of the platelet IIb/IIIa receptor with integrilin. Am J Cardiol 2002;89:61-64.
7. Fernandes LS, Tcheng JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol 2002;40:1085-1091.
8. Granada JF and Kleiman NS. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting. Am J Cardiovasc Drugs 2004;4:31-41.
9. Kereiakes DJ, Lincoff M, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 1998;97:857-864.
10. Kini AS, Richard M, Suleman J, et al. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol 2002;90:526-529.
11. Kleiman NS, Lincoff M, Kereiakes DJ, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998;97:1912-1920.
12. Konstance R, Tcheng JE, Wightman MB, et al. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. J Interv Cardiol 2004;17:65-70.
13. Niebauer J, Sixt S, Zhang F, et al. Contemporary outcome of cardiac catheterizations in 1085 consecutive octogenarians. Int J Cardiol 2004;93:225-230.
14. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA 2001;285:2468-2473.
15. O'Shea JC and Tcheng JE. Eptifibatide in oercutaneous coronary intervention: The ESPRIT Trial results. Curr Interv Cardiol Rep 2001;3:62-68.
16. Rinder MR, Tamirisa PK, Taniuchi M, et al. Safety and efficacy of suture-mediated closure after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;54:146-151.
17. Shaw JA, Dewire E, Nugent A, et al. Use of suture-mediated vascular closure devices for the management of femoral vein access after transcatheter procedures. Catheter Cardiovasc Interv 2004;63:439-443.
18. Noto TJ, Johnson LW, Krone R, et al. Cardiac catheterization 1990: A report of the registry of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn 1991;24:75.
19. Safian RD, Freed MS. Coronary intervention preparation, equipment and technique. In: Safian RD, Freed MS (eds). The Manual of Interventional Cardiology, 3rd edition. Royal Oak, MI: Physicians' Press; 2001.
20. Baim DS, Grossman W. Complications of cardiac catheterization. In: Baim DS, Grossman W (eds). Grossman's Cardiac Catheterization, Angiography, and Intervention, 6th edition. Philadelphia: Lippincott Williams and Wilkins; 2000: pp. 35-65.
21. Toursarkissian B. Changing patterns of access site complications with the use of percutaneous closure devices. Vasc Surg 2001;35:203-206.
22. Exaire JE, Tcheng JE, Kereiakes DJ, et al. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv 2005;64:369-372.